Dr. Weihsi Chen
Institute of Nuclear Energy Research, Tai Wan
1998 Ph.D., Chemistry Department, National Taiwan University, Taiwan, China
1990 M.D., Chemistry Department, National Taiwan University, Taiwan, China
Chen WH, et al.: Determination of the metabolites of FEONM, an Alzheimer’s disease radio-imaging diagnosis agent in various biosystems using LC/Tandem Mass Spectrometry. (2017) EC Pharmacology and Toxicology 4.2: 40-50.
Chen WH, et al.: Liquid chromatography-mass spectrometry to monitor the labeling process stability and identify derivatives during the preparation of 188Re-MN-16ET: A
radiopharmaceutical for hepatoma. (2017) Pharmaceutical Analytical Chemistry 3:1 DOI: 10.4172/2471-2698.1000121
Chen WH, et al.: Identification of impurities and forced degradation characterization of protected–H3MN-16ET 16ET, a precursor for radiotherapy of hepatoma using liquid chromatography tandem mass spectrometry. (2016) International Journal of Chemical and Pharmaceutical Analysis V.3, I.2, Article ID: 877.
Chen WH, et al.: High performance liquid chromatography-tandem mass spectrometry method for ex vivo metabolic studies of a rhenium-labeled radiopharmaceutical for liver cancer. (2014) Eur. J. Mass Spectrom. 20, 375–382
Chen WH, et. al.: Forced degradation behavior of epidepride and development of a stability-indicating method based on liquid chromatography-mass spectrometry. (2014) J. Food and Drug Analysis 22, 248-256.